Galectins: Major signaling modulators inside and outside the cell

Current Molecular Medicine

Volumn 14, Issue 5, 2014, Pages 630-651

  Compagno, D ^a   Jaworski, F M ^a   Gentilini, L ^a   Contrufo, G ^a   Pérez, I González ^a   Elola, M T ^a   Pregi, N ^a   Rabinovich, G A ^a,b   Laderach, D J ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b INST DE BIOL Y MED EXPERIMENTAL   (Argentina)

Author keywords

Apoptosis; Cell adherence; Galectins; Immune regulation; Oncogenesis; Signaling pathways

Indexed keywords

CD45 ANTIGEN; CD98 ANTIGEN; GALECTIN; GLYCOCONJUGATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL 2; RAS PROTEIN; SMAD3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE;

APOPTOSIS; CELL MIGRATION; CELL PROLIFERATION; DOWNREGULATION; GENE CONTROL; HUMAN; NUCLEAR LOCALIZATION SIGNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REVIEW; SIGNAL TRANSDUCTION; SPLICEOSOME; T LYMPHOCYTE; TANDEM REPEAT; ANIMAL; CARCINOGENESIS; CELL ADHESION; METABOLISM; PHYSIOLOGY;

ANIMALS; CARCINOGENESIS; CELL ADHESION; GALECTINS; HUMANS; SIGNAL TRANSDUCTION;

EID: 84904036236     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/1566524014666140603101953     Document Type: Review

References (245)

1. Vasta GR. Galectins as pattern recognition receptors: structure, function, and evolution. Adv Exp Med Biol 2012; 946: 21-36.
2. Rabinovich GA, Toscano MA. Turning 'sweet' on immunity: galectin-glycan interactions in immune tolerance and inflammation. Nat Rev Immunol 2009; 9: 338-52.
3. Hirabayashi J, Kasai K. The family of metazoan metalindependent beta-galactoside-binding lectins: structure, function and molecular evolution. Glycobiology 1993; 3: 297-304.
4. Barondes SH, Castronovo V, Cooper DN, et al. Galectins: a family of animal beta-galactoside-binding lectins. Cell 1994; 76: 597-8.
5. Leffler H, Carlsson S, Hedlund M, Qian Y, Poirier F. Introduction to galectins. Glycoconj J 2004; 19: 433-40.
6. Rabinovich GA, Baum LG, Tinari N, et al. Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response? Trends Immunol 2002; 23: 313-20.
7. Rabinovich GA, Croci DO. Regulatory circuits mediated by lectin-glycan interactions in autoimmunity and cancer. Immunity 2012; 36: 322-35.
8. Gabius HJ, Wu AM. The emerging functionality of endogenous lectins: A primer to the concept and a case study on galectins including medical implications. Chang Gung Med J 2006; 29: 37-62.
9. Laderach DJ, Compagno D, Toscano MA, et al. Dissecting the signal transduction pathways triggered by galectin-glycan interactions in physiological and pathological settings. IUBMB Life 2010; 62: 1-13.
10. Gabius HJ, Andre S, Jimenez-Barbero J, Romero A, Solis D. From lectin structure to functional glycomics: principles of the sugar code. Trends Biochem Sci 2011; 36: 298-313.
11. Agrwal N, Wang JL, Voss PG. Carbohydrate-binding protein 35. Levels of transcription and mRNA accumulation in quiescent and proliferating cells. J Biol Chem 1989; 264: 17236-42.
12. Openo KP, Kadrofske MM, Patterson RJ, Wang JL. Galectin- 3 expression and subcellular localization in senescent human fibroblasts. Exp Cell Res 2000; 255: 278-90.
13. Hamann KK, Cowles EA, Wang JL, Anderson RL. Expression of carbohydrate binding protein 35 in human fibroblasts: variations in the levels of mRNA, protein, and isoelectric species as a function of replicative competence. Exp Cell Res 1991; 196: 82-91.
14. Cho M, Cummings RD. Galectin-1, a beta-galactosidebinding lectin in Chinese hamster ovary cells. I. Physical and chemical characterization. J Biol Chem 1995; 270: 5198-206.
15. Leppanen A, Stowell S, Blixt O, Cummings RD. Dimeric galectin-1 binds with high affinity to alpha2,3-sialylated and non-sialylated terminal N-acetyllactosamine units on surfacebound extended glycans. J Biol Chem 2005; 280: 5549-62.
16. Morris S, Ahmad N, Andre S, et al. Quaternary solution structures of galectins-1, -3, and -7. Glycobiology 2004; 14: 293-300.
17. Ahmad N, Gabius HJ, Andre S, et al. Galectin-3 precipitates as a pentamer with synthetic multivalent carbohydrates and forms heterogeneous cross-linked complexes. J Biol Chem 2004; 279: 10841-7.
18. Davidson PJ, Davis MJ, Patterson RJ, Ripoche MA, Poirier F, Wang JL. Shuttling of galectin-3 between the nucleus and cytoplasm. Glycobiology 2002; 12: 329-37.
19. Davidson PJ, Li SY, Lohse AG, et al. Transport of galectin-3 between the nucleus and cytoplasm. I. Conditions and signals for nuclear import. Glycobiology 2006; 16: 602-11.
20. Nakahara S, Oka N, Wang Y, Hogan V, Inohara H, Raz A. Characterization of the nuclear import pathways of galectin- 3. Cancer Res 2006; 66: 9995-10006.
21. Paces-Fessy M, Boucher D, Petit E, Paute-Briand S, Blanchet-Tournier MF. The negative regulator of Gli, Suppressor of fused (Sufu), interacts with SAP18, Galectin3 and other nuclear proteins. Biochem J 2004; 378: 353-62.
22. Hughes RC. Secretion of the galectin family of mammalian carbohydrate-binding proteins. Biochim Biophys Acta 1999; 1473: 172-85.
23. Cowles EA, Agrwal N, Anderson RL, Wang JL. Carbohydrate-binding protein 35. Isoelectric points of the polypeptide and a phosphorylated derivative. J Biol Chem 1990; 265: 17706-12.
24. Huflejt ME, Turck CW, Lindstedt R, Barondes SH, Leffler H. L-29, a soluble lactose-binding lectin, is phosphorylated on serine 6 and serine 12 in vivo and by casein kinase I. J Biol Chem 1993; 268: 26712-8.
25. Mazurek N, Conklin J, Byrd JC, Raz A, Bresalier RS. Phosphorylation of the beta-galactoside-binding protein galectin-3 modulates binding to its ligands. J Biol Chem 2000; 275: 36311-5.
26. Yoshii T, Fukumori T, Honjo Y, Inohara H, Kim HR, Raz A. Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest. J Biol Chem 2002; 277: 6852-6857.
27. Frigeri LG, Robertson MW, Liu FT. Expression of biologically active recombinant rat IgE-binding protein in Escherichia coli. J Biol Chem 1990; 265: 20763-9.
28. Gohler A, Buchner C, Andre S, Soren D, Kaltner H, Gabius HJ. Analysis of homodimeric avian and human galectins by two methods based on fluorescence spectroscopy: different structural alterations upon oxidation and ligand binding. Biochimie 2012; 94: 2649-55.
29. Herrmann J, Turck CW, Atchison RE, et al. Primary structure of the soluble lactose binding lectin L-29 from rat and dog and interaction of its non-collagenous proline-, glycine-, tyrosine-rich sequence with bacterial and tissue collagenase. J Biol Chem 1993; 268: 26704-11.
30. Vyakarnam A, Lenneman AJ, Lakkides KM, Patterson RJ, Wang JL. A comparative nuclear localization study of galectin-1 with other splicing components. Exp Cell Res 1998; 242: 419-28.
31. Gaudin JC, Mehul B, Hughes RC. Nuclear localisation of wild type and mutant galectin-3 in transfected cells. Biol Cell 2000; 92: 49-58.
32. Sato S, Burdett I, Hughes RC. Secretion of the baby hamster kidney 30-kDa galactose-binding lectin from polarized and nonpolarized cells: a pathway independent of the endoplasmic reticulum-Golgi complex. Exp Cell Res 1993; 207: 8-18.
33. Amano M, Eriksson H, Manning JC, et al. Tumour suppressor p16(INK4a) - anoikis-favouring decrease in N/Oglycan/ cell surface sialylation by down-regulation of enzymes in sialic acid biosynthesis in tandem in a pancreatic carcinoma model. Febs J 2012; 279: 4062-80.
34. Paron I, Scaloni A, Pines A, et al. Nuclear localization of Galectin-3 in transformed thyroid cells: a role in transcriptional regulation. Biochem Biophys Res Commun 2003; 302: 545-53.
35. Yu X, Siegel R, Roeder RG. Interaction of the B cell-specific transcriptional coactivator OCA-B and galectin-1 and a possible role in regulating BCR-mediated B cell proliferation. J Biol Chem 2006; 281: 15505-16.
36. Felin M, Doyennette-Moyne MA, Hadj-Sahraoui Y, Aubery M, Hubert J, Seve AP. Identification of two nuclear Nacetylglucosamine- binding proteins. J Cell Biochem 1994; 56: 527-35.
37. Lin HM, Pestell RG, Raz A, Kim HR. Galectin-3 enhances cyclin D(1) promoter activity through SP1 and a cAMPresponsive element in human breast epithelial cells. Oncogene 2002; 21: 8001-10.
38. Vyakarnam A, Dagher SF, Wang JL, Patterson RJ. Evidence for a role for galectin-1 in pre-mRNA splicing. Mol Cell Biol 1997; 17: 4730-7.
39. Park JW, Voss PG, Grabski S, Wang JL, Patterson RJ. Association of galectin-1 and galectin-3 with Gemin4 in complexes containing the SMN protein. Nucleic Acids Res 2001; 29: 3595-602.
40. Fakan S, Leser G, Martin TE. Ultrastructural distribution of nuclear ribonucleoproteins as visualized by immunocytochemistry on thin sections. J Cell Biol 1984; 98: 358-63.
41. Charroux B, Pellizzoni L, Perkinson RA, et al. Gemin4. A novel component of the SMN complex that is found in both gems and nucleoli. J Cell Biol 2000; 148: 1177-86.
42. Mourelatos Z, Dostie J, Paushkin S, et al. miRNPs: a novel class of ribonucleoproteins containing numerous microRNAs. Genes Dev 2002; 16: 720-8.
43. Paushkin S, Gubitz AK, Massenet S, Dreyfuss G. The SMN complex, an assemblyosome of ribonucleoproteins. Curr Opin Cell Biol 2002; 14: 305-12.
44. Fischer U, Liu Q, Dreyfuss G. The SMN-SIP1 complex has an essential role in spliceosomal snRNP biogenesis. Cell 1997; 90: 1023-9.
45. Dagher SF, Wang JL, Patterson RJ. Identification of galectin- 3 as a factor in pre-mRNA splicing. Proc Natl Acad Sci U S A 1995; 92: 1213-7.
46. Laing JG, Wang JL. Identification of carbohydrate binding protein 35 in heterogeneous nuclear ribonucleoprotein complex. Biochemistry 1988; 27: 5329-34.
47. Wang L, Inohara H, Pienta KJ, Raz A. Galectin-3 is a nuclear matrix protein which binds RNA. Biochem Biophys Res Commun 1995; 217: 292-303.
48. Wang W, Park JW, Wang JL, Patterson RJ. Immunoprecipitation of spliceosomal RNAs by antisera to galectin-1 and galectin-3. Nucleic Acids Res 2006; 34: 5166-74.
49. Voss PG, Gray RM, Dickey SW, et al. Dissociation of the carbohydrate-binding and splicing activities of galectin-1. Arch Biochem Biophys 2008; 478: 18-25.
50. Haudek KC, Voss PG, Locascio LE, Wang JL, Patterson RJ. A mechanism for incorporation of galectin-3 into the spliceosome through its association with U1 snRNP. Biochemistry 2009; 48: 7705-12.
51. Demers M, Rose AA, Grosset AA, et al. Overexpression of galectin-7, a myoepithelial cell marker, enhances spontaneous metastasis of breast cancer cells. Am J Pathol 2010; 176: 3023-31.
52. Inagaki Y, Higashi K, Kushida M, et al. Hepatocyte growth factor suppresses profibrogenic signal transduction via nuclear export of Smad3 with galectin-7. Gastroenterology 2008; 134: 1180-90.
53. Matsuura A, Tsukada J, Mizobe T, et al. Intracellular galectin-9 activates inflammatory cytokines in monocytes. Genes Cells 2009; 14: 511-21.
54. Zhu C, Anderson AC, Schubart A, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 2005; 6: 1245-52.
55. Oomizu S, Arikawa T, Niki T, et al. Cell surface galectin-9 expressing th cells regulate Th17 and Foxp3+ Treg development by galectin-9 secretion. PLoS One 2012; 7: e48574.
56. Delgado VM, Nugnes LG, Colombo LL, et al. Modulation of endothelial cell migration and angiogenesis: a novel function for the tandem-repeat lectin galectin-8. Faseb J 2011; 25: 242-54.
57. Dvorak AM, Ackerman SJ, Furitsu T, Estrella P, Letourneau L, Ishizaka T. Mature eosinophils stimulated to develop in human-cord blood mononuclear cell cultures supplemented with recombinant human interleukin-5. II. Vesicular transport of specific granule matrix peroxidase, a mechanism for effecting piecemeal degranulation. Am J Pathol 1992; 140: 795-807.
58. Dunphy JL, Balic A, Barcham GJ, Horvath AJ, Nash AD, Meeusen EN. Isolation and characterization of a novel inducible mammalian galectin. J Biol Chem 2000; 275: 32106-13.
59. Hotta K, Funahashi T, Matsukawa Y, et al. Galectin-12, an Adipose-expressed Galectin-like Molecule Possessing Apoptosis-inducing Activity. J Biol Chem 2001; 276: 34089-97.
60. Dunphy JL, Barcham GJ, Bischof RJ, Young AR, Nash A, Meeusen EN. Isolation and characterization of a novel eosinophil-specific galectin released into the lungs in response to allergen challenge. J Biol Chem 2002; 277: 14916-24.
61. Dvorankova B, Lacina L, Smetana K, Jr., et al. Human galectin-2: nuclear presence in vitro and its modulation by quiescence/stress factors. Histol Histopathol 2008; 23: 167-78.
62. Saussez S, Decaestecker C, Lorfevre F, et al. Increased expression and altered intracellular distribution of adhesion/growth-regulatory lectins galectins-1 and -7 during tumour progression in hypopharyngeal and laryngeal squamous cell carcinomas. Histopathology 2008; 52: 483-93.
63. Yu F, Finley RL, Jr., Raz A, Kim HR. Galectin-3 translocates to the perinuclear membranes and inhibits cytochrome c release from the mitochondria. A role for synexin in galectin- 3 translocation. J Biol Chem 2002; 277: 15819-27.
64. Kim DW, Kim KH, Yoo BC, et al. Identification of mitochondrial F(1)F(0)-ATP synthase interacting with galectin-3 in colon cancer cells. Cancer Sci 2008; 99: 1884-91.
65. Yang RY, Hsu DK, Liu FT. Expression of galectin-3 modulates T-cell growth and apoptosis. Proc Natl Acad Sci U S A 1996; 93: 6737-42.
66. Akahani S, Nangia-Makker P, Inohara H, Kim HR, Raz A. Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res 1997; 57: 5272-6.
67. Cheng YL, Huang WC, Chen CL, et al. Increased galectin-3 facilitates leukemia cell survival from apoptotic stimuli. Biochem Biophys Res Commun 2011; 412: 334-40.
68. Villeneuve C, Baricault L, Canelle L, et al. Mitochondrial proteomic approach reveals galectin-7 as a novel BCL-2 binding protein in human cells. Mol Biol Cell 2011; 22: 999-1013.
69. Fuertes MB, Molinero LL, Toscano MA, et al. Regulated expression of galectin-1 during T-cell activation involves Lck and Fyn kinases and signaling through MEK1/ERK, p38 MAP kinase and p70S6 kinase. Mol Cell Biochem 2004; 267: 177-85.
70. Ilarregui JM, Croci DO, Bianco GA, et al. Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1- driven immunoregulatory circuit involving interleukin 27 and interleukin 10. Nat Immunol 2009; 10: 981-91.
71. Toscano MA, Campagna L, Molinero LL, et al. Nuclear factor (NF)-kappaB controls expression of the immunoregulatory glycan-binding protein galectin-1. Mol Immunol 2011; 48: 1940-9.
72. Liu SD, Tomassian T, Bruhn KW, Miller JF, Poirier F, Miceli MC. Galectin-1 tunes TCR binding and signal transduction to regulate CD8 burst size. J Immunol 2009; 182: 5283-95.
73. Toscano MA, Bianco GA, Ilarregui JM, et al. Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death. Nat Immunol 2007; 8: 825-34.
74. Espeli M, Mancini SJ, Breton C, Poirier F, Schiff C. Impaired B cell development at the pre-BII cell stage in galectin-1 deficient mice due to inefficient pre-BII-stromal cell interactions. Blood 2009; 113: 5878-86.
75. Zuniga E, Rabinovich GA, Iglesias MM, Gruppi A. Regulated expression of galectin-1 during B-cell activation and implications for T-cell apoptosis. J Leukoc Biol 2001; 70: 73-9.
76. Tsai CM, Guan CH, Hsieh HW, et al. Galectin-1 and galectin- 8 have redundant roles in promoting plasma cell formation. J Immunol 2011; 187: 1643-52.
77. Tsai CM, Chiu YK, Hsu TL, Lin IY, Hsieh SL, Lin KI. Galectin- 1 promotes immunoglobulin production during plasma cell differentiation. J Immunol 2008; 181: 4570-9.
78. Tabrizi SJ, Niiro H, Masui M, et al. T cell leukemia/lymphoma 1 and galectin-1 regulate survival/cell death pathways in human naive and IgM+ memory B cells through altering balances in Bcl-2 family proteins. J Immunol 2009; 182: 1490-9.
79. Starossom SC, Mascanfroni ID, Imitola J, et al. Galectin-1 deactivates classically activated microglia and protects from inflammation-induced neurodegeneration. Immunity 2012; 37: 249-63.
80. Wang Y, Balan V, Kho D, Hogan V, Nangia-Makker P, Raz A. Galectin-3 regulates p21 stability in human prostate cancer cells. Oncogene 2012: 32: 5058-65.
81. Yamazaki K, Kawai A, Kawaguchi M, et al. Simultaneous induction of galectin-3 phosphorylated on tyrosine residue, p21(WAF1/Cip1/Sdi1), and the proliferating cell nuclear antigen at a distinctive period of repair of hepatocytes injured by CCl4. Biochem Biophys Res Commun 2001; 280: 1077-84.
82. Nakahara S, Oka N, Raz A. On the role of galectin-3 in cancer apoptosis. Apoptosis 2005; 10: 267-75.
83. Saegusa J, Hsu DK, Liu W, et al. Galectin-3 protects keratinocytes from UVB-induced apoptosis by enhancing AKT activation and suppressing ERK activation. J Invest Dermatol 2008; 128: 2403-11.
84. Califice S, Castronovo V, Bracke M, van den Brule F. Dual activities of galectin-3 in human prostate cancer: tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3. Oncogene 2004; 23: 7527-36.
85. Brand C, Oliveira FL, Ricon L, et al. The bone marrow compartment is modified in the absence of galectin-3. Cell Tissue Res 2011; 346: 427-37.
86. Hsu DK, Yang RY, Pan Z, et al. Targeted disruption of the galectin-3 gene results in attenuated peritoneal inflammatory responses. Am J Pathol 2000; 156: 1073-83.
87. MacKinnon AC, Farnworth SL, Hodkinson PS, et al. Regulation of alternative macrophage activation by galectin- 3. J Immunol 2008; 180: 2650-8.
88. Acosta-Rodriguez EV, Montes CL, Motran CC, et al. Galectin-3 mediates IL-4-induced survival and differentiation of B cells: functional cross-talk and implications during Trypanosoma cruzi infection. J Immunol 2004; 172: 493-502.
89. Oliveira FL, Brand C, Paula AA, et al. Lack of galectin-3 disturbs mesenteric lymph node homeostasis and B cell niches in the course of Schistosoma mansoni infection. PLoS One 2011; 6: e19216.
90. Menon RP, Strom M, Hughes RC. Interaction of a novel cysteine and histidine-rich cytoplasmic protein with galectin-3 in a carbohydrate-independent manner. FEBS Lett 2000; 470: 227-31.
91. Bawumia S, Barboni EA, Menon RP, Hughes RC. Specificity of interactions of galectin-3 with Chrp, a cysteine- and histidine-rich cytoplasmic protein. Biochimie 2003; 85: 189-94.
92. Goletz S, Hanisch FG, Karsten U. Novel alphaGalNAc containing glycans on cytokeratins are recognized invitro by galectins with type II carbohydrate recognition domains. J Cell Sci 1997; 110 (Pt 14): 1585-96.
93. Paz A, Haklai R, Elad-Sfadia G, Ballan E, Kloog Y. Galectin- 1 binds oncogenic H-Ras to mediate Ras membrane anchorage and cell transformation. Oncogene 2001; 20: 7486-93.
94. Rotblat B, Belanis L, Liang H, et al. H-Ras nanocluster stability regulates the magnitude of MAPK signal output. PLoS One 2004; 5: e11991.
95. Belanis L, Plowman SJ, Rotblat B, Hancock JF, Kloog Y. Galectin-1 is a novel structural component and a major regulator of h-ras nanoclusters. Mol Biol Cell 2008; 19: 1404-14.
96. Elad-Sfadia G, Haklai R, Ballan E, Gabius HJ, Kloog Y. Galectin-1 augments Ras activation and diverts Ras signals to Raf-1 at the expense of phosphoinositide 3-kinase. J Biol Chem 2002; 277: 37169-75.
97. Vernitsky H, Rechavi O, Rainy N, et al. Ras oncoproteins transfer from melanoma cells to T cells and modulate their effector functions. J Immunol 2012; 189: 4361-70.
98. Shalom-Feuerstein R, Plowman SJ, Rotblat B, et al. K-ras nanoclustering is subverted by overexpression of the scaffold protein galectin-3. Cancer Res 2008; 68: 6608-16.
99. Song S, Mazurek N, Liu C, et al. Galectin-3 mediates nuclear beta-catenin accumulation and Wnt signaling in human colon cancer cells by regulation of glycogen synthase kinase-3beta activity. Cancer Res 2009; 69: 1343-9.
100. Song S, Ji B, Ramachandran V, et al. Overexpressed galectin-3 in pancreatic cancer induces cell proliferation and invasion by binding Ras and activating Ras signaling. PLoS One 2012; 7: e42699.
101. Levy R, Grafi-Cohen M, Kraiem Z, Kloog Y. Galectin-3 promotes chronic activation of K-Ras and differentiation block in malignant thyroid carcinomas. Mol Cancer Ther 2010; 9: 2208-19.
102. Koch A, Poirier F, Jacob R, Delacour D. Galectin-3, a novel centrosome-associated protein, required for epithelial morphogenesis. Mol Biol Cell 2010; 21: 219-31.
103. Chiu MG, Johnson TM, Woolf AS, et al. Galectin-3 associates with the primary cilium and modulates cyst growth in congenital polycystic kidney disease. Am J Pathol 2006; 169: 1925-38.
104. Hsu DK, Chernyavsky AI, Chen HY, Yu L, Grando SA, Liu FT. Endogenous galectin-3 is localized in membrane lipid rafts and regulates migration of dendritic cells. J Invest Dermatol 2009; 129: 573-83.
105. Chen HY, Fermin A, Vardhana S, et al. Galectin-3 negatively regulates TCR-mediated CD4+ T-cell activation at the immunological synapse. Proc Natl Acad Sci U S A 2009; 106: 14496-501.
106. Granovsky M, Fata J, Pawling J, Muller WJ, Khokha R, Dennis JW. Suppression of tumor growth and metastasis in Mgat5-deficient mice. Nat Med 2000; 6: 306-12.
107. Dube DH, Bertozzi CR. Glycans in cancer and inflammation-- potential for therapeutics and diagnostics. Nat Rev Drug Discov 2005; 4: 477-88.
108. Fajka-Boja R, Blasko A, Kovacs-Solyom F, Szebeni GJ, Toth GK, Monostori E. Co-localization of galectin-1 with GM1 ganglioside in the course of its clathrin- and raft-dependent endocytosis. Cell Mol Life Sci 2008; 65: 2586-93.
109. Tanikawa R, Tanikawa T, Okada Y, et al. Interaction of galectin-9 with lipid rafts induces osteoblast proliferation through the c-Src/ERK signaling pathway. J Bone Miner Res 2008; 23: 278-86.
110. Kopitz J, Ballikaya S, Andre S, Gabius HJ. Ganglioside GM1/galectin-dependent growth regulation in human neuroblastoma cells: special properties of bivalent galectin-4 and significance of linker length for ligand selection. Neurochem Res 2012; 37: 1267-76.
111. Garner OB, Baum LG. Galectin-glycan lattices regulate cellsurface glycoprotein organization and signaling. Biochem Soc Trans 2008; 36: 1472-7.
112. Earl LA, Bi S, Baum LG. N- and O-glycans modulate galectin-1 binding, CD45 signaling, and T cell death. J Biol Chem 2010; 285: 2232-44.
113. Walzel H, Fahmi AA, Eldesouky MA, et al. Effects of Nglycan processing inhibitors on signaling events and induction of apoptosis in galectin-1-stimulated Jurkat T lymphocytes. Glycobiology 2006; 16: 1262-71.
114. Motran CC, Molinder KM, Liu SD, Poirier F, Miceli MC. Galectin-1 functions as a Th2 cytokine that selectively induces Th1 apoptosis and promotes Th2 function. Eur J Immunol 2008; 38: 3015-27.
115. Endharti AT, Zhou YW, Nakashima I, Suzuki H. Galectin-1 supports survival of naive T cells without promoting cell proliferation. Eur J Immunol 2005; 35: 86-97.
116. Brandt B, Buchse T, Abou-Eladab EF, et al. Galectin-1 induced activation of the apoptotic death-receptor pathway in human Jurkat T lymphocytes. Histochem Cell Biol 2008; 129: 599-609.
117. Lange F, Brandt B, Tiedge M, et al. Galectin-1 induced activation of the mitochondrial apoptotic pathway: evidence for a connection between death-receptor and mitochondrial pathways in human Jurkat T lymphocytes. Histochem Cell Biol 2009; 132: 211-23.
118. Ion G, Fajka-Boja R, Kovacs F, et al. Acid sphingomyelinase mediated release of ceramide is essential to trigger the mitochondrial pathway of apoptosis by galectin-1. Cell Signal 2006; 18: 1887-96.
119. Rabinovich GA, Alonso CR, Sotomayor CE, Durand S, Bocco JL, Riera CM. Molecular mechanisms implicated in galectin-1-induced apoptosis: activation of the AP-1 transcription factor and downregulation of Bcl-2. Cell Death Differ 2000; 7: 747-53.
120. Pace KE, Hahn HP, Pang M, Nguyen JT, Baum LG. CD7 delivers a pro-apoptotic signal during galectin-1-induced T cell death. J Immunol 2000; 165: 2331-4.
121. Hahn HP, Pang M, He J, et al. Galectin-1 induces nuclear translocation of endonuclease G in caspase- and cytochrome c-independent T cell death. Cell Death Differ 2004; 11: 1277-86.
122. van der Leij J, van den Berg A, Harms G, et al. Strongly enhanced IL-10 production using stable galectin-1 homodimers. Mol Immunol 2007; 44: 506-13.
123. Earl LA, Bi S, Baum LG. Galectin multimerization and lattice formation are regulated by linker region structure. Glycobiology 2011; 21: 6-12.
124. Cedeno-Laurent F, Barthel SR, Opperman MJ, Lee DM, Clark RA, Dimitroff CJ. Development of a nascent galectin-1 chimeric molecule for studying the role of leukocyte galectin- 1 ligands and immune disease modulation. J Immunol 2010; 185: 4659-72.
125. Ellerhorst J, Nguyen T, Cooper DN, Estrov Y, Lotan D, Lotan R. Induction of differentiation and apoptosis in the prostate cancer cell line LNCaP by sodium butyrate and galectin-1. Int J Oncol 1999; 14: 225-32.
126. Stowell SR, Karmakar S, Arthur CM, et al. Galectin-1 induces reversible phosphatidylserine exposure at the plasma membrane. Mol Biol Cell 2009; 20: 1408-18.
127. Garin MI, Chu CC, Golshayan D, Cernuda-Morollon E, Wait R, Lechler RI. Galectin-1: a key effector of regulation mediated by CD4+CD25+ T cells. Blood 2007; 109: 2058-65.
128. Sugimoto N, Oida T, Hirota K, et al. Foxp3-dependent and - independent molecules specific for CD25+CD4+ natural regulatory T cells revealed by DNA microarray analysis. Int Immunol 2006; 18: 1197-209.
129. Baatar D, Olkhanud PB, Wells V, Indig FE, Mallucci L, Biragyn A. Tregs utilize beta-galactoside-binding protein to transiently inhibit PI3K/p21ras activity of human CD8+ T cells to block their TCR-mediated ERK activity and proliferation. Brain Behav Immun 2009; 23: 1028-37.
130. Wang J, Lu ZH, Gabius HJ, Rohowsky-Kochan C, Ledeen RW, Wu G. Cross-linking of GM1 ganglioside by galectin-1 mediates regulatory T cell activity involving TRPC5 channel activation: possible role in suppressing experimental autoimmune encephalomyelitis. J Immunol 2009; 182: 4036-45.
131. Cedeno-Laurent F, Opperman M, Barthel SR, Kuchroo VK, Dimitroff CJ. Galectin-1 triggers an immunoregulatory signature in Th cells functionally defined by IL-10 expression. J Immunol 2012; 188: 3127-37.
132. Kubach J, Lutter P, Bopp T, et al. Human CD4+CD25+ regulatory T cells: proteome analysis identifies galectin-10 as a novel marker essential for their anergy and suppressive function. Blood 2007; 110: 1550-8.
133. Barrionuevo P, Beigier-Bompadre M, Ilarregui JM, et al. A novel function for galectin-1 at the crossroad of innate and adaptive immunity: galectin-1 regulates monocyte/macrophage physiology through a nonapoptotic ERK-dependent pathway. J Immunol 2007; 178: 436-45.
134. Malik RK, Ghurye RR, Lawrence-Watt DJ, Stewart HJ. Galectin-1 stimulates monocyte chemotaxis via the p44/42 MAP kinase pathway and a pertussis toxin-sensitive pathway. Glycobiology 2009; 19: 1402-7.
135. Ortner D, Grabher D, Hermann M, Kremmer E, Hofer S, Heufler C. The adaptor protein Bam32 in human dendritic cells participates in the regulation of MHC class I-induced CD8+ T cell activation. J Immunol 2011; 187: 3972-8.
136. Fulcher JA, Hashimi ST, Levroney EL, et al. Galectin-1- matured human monocyte-derived dendritic cells have enhanced migration through extracellular matrix. J Immunol 2006; 177: 216-26.
137. Fulcher JA, Chang MH, Wang S, et al. Galectin-1 co-clusters CD43/CD45 on dendritic cells and induces cell activation and migration through Syk and protein kinase C signaling. J Biol Chem 2009; 284: 26860-70.
138. Mourcin F, Breton C, Tellier J, et al. Galectin-1-expressing stromal cells constitute a specific niche for pre-BII cell development in mouse bone marrow. Blood 2011; 117: 6552-61.
139. Elantak L, Espeli M, Boned A, et al. Structural Basis for Galectin-1-dependent Pre-B Cell Receptor (Pre-BCR) Activation. J Biol Chem 2012; 287: 44703-13.
140. Gauthier L, Rossi B, Roux F, Termine E, Schiff C. Galectin-1 is a stromal cell ligand of the pre-B cell receptor (BCR) implicated in synapse formation between pre-B and stromal cells and in pre-BCR triggering. Proc Natl Acad Sci U S A 2002; 99: 13014-9.
141. Rossi B, Espeli M, Schiff C, Gauthier L. Clustering of pre-B cell integrins induces galectin-1-dependent pre-B cell receptor relocalization and activation. J Immunol 2006; 177: 796-803.
142. Lecourt S, Lepelletier Y, Vanneaux V, et al. Human Muscle Progenitor Cells Displayed Immunosuppressive Effect through Galectin-1 and Semaphorin-3A. Stem Cells Int 2012; 2012: 412610.
143. Lepelletier Y, Lecourt S, Renand A, et al. Galectin-1 and semaphorin-3A are two soluble factors conferring T-cell immunosuppression to bone marrow mesenchymal stem cell. Stem Cells Dev 2010; 19: 1075-9.
144. Jouve N, Despoix N, Espeli M, et al. The involvement of CD146 and its novel ligand Galectin-1 in apoptotic regulation of endothelial cells. J Biol Chem 2011; 288: 2571-9.
145. Hsieh SH, Ying NW, Wu MH, et al. Galectin-1, a novel ligand of neuropilin-1, activates VEGFR-2 signaling and modulates the migration of vascular endothelial cells. Oncogene 2008; 27: 3746-53.
146. Laderach DJ, Gentilini LD, Giribaldi L, et al. A Unique Galectin Signature in Human Prostate Cancer Progression Suggests Galectin-1 as a Key Target for Treatment of Advanced Disease. Cancer Res 2013; 73: 86-96.
147. Croci DO, Salatino M, Rubinstein N, et al. Disrupting galectin-1 interactions with N-glycans suppresses hypoxiadriven angiogenesis and tumorigenesis in Kaposi's sarcoma. J Exp Med 2012; 209: 1985-2000.
148. Fischer I, Weber M, Kuhn C, et al. Is galectin-1 a trigger for trophoblast cell fusion?: the MAP-kinase pathway and syncytium formation in trophoblast tumour cells BeWo. Mol Hum Reprod 2011; 17: 747-57.
149. Fischer I, Schulze S, Kuhn C, et al. Inhibiton of RET and JAK2 signals and upregulation of VEGFR3 phosphorylation in vitro by galectin-1 in trophoblast tumor cells BeWo. Placenta 2009; 30: 1078-82.
150. Thijssen VL, Postel R, Brandwijk RJ, et al. Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci U S A 2006; 103: 15975-80.
151. Sturm A, Lensch M, Andre S, et al. Human galectin-2: novel inducer of T cell apoptosis with distinct profile of caspase activation. J Immunol 2004; 173: 3825-37.
152. Kashio Y, Nakamura K, Abedin MJ, et al. Galectin-9 induces apoptosis through the calcium-calpain-caspase-1 pathway. J Immunol 2003; 170: 3631-6.
153. Oomizu S, Arikawa T, Niki T, et al. Galectin-9 suppresses Th17 cell development in an IL-2-dependent but Tim-3- independent manner. Clin Immunol 2012; 143: 51-8.
154. Lu LH, Nakagawa R, Kashio Y, et al. Characterization of galectin-9-induced death of Jurkat T cells. J Biochem 2007; 141: 157-72.
155. Dai SY, Nakagawa R, Itoh A, et al. Galectin-9 induces maturation of human monocyte-derived dendritic cells. J Immunol 2005; 175: 2974-81.
156. Wang F, Wan L, Zhang C, Zheng X, Li J, Chen ZK. Tim-3- Galectin-9 pathway involves the suppression induced by CD4+CD25+ regulatory T cells. Immunobiology 2009; 214: 342-9.
157. Seki M, Oomizu S, Sakata KM, et al. Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis. Clin Immunol 2008; 127: 78-88.
158. Imaizumi T, Yoshida H, Nishi N, et al. Double-stranded RNA induces galectin-9 in vascular endothelial cells: involvement of TLR3, PI3K, and IRF3 pathway. Glycobiology 2007; 17: 12C-5C.
159. Tanikawa R, Tanikawa T, Hirashima M, Yamauchi A, Tanaka Y. Galectin-9 induces osteoblast differentiation through the CD44/Smad signaling pathway. Biochem Biophys Res Commun 2010; 394: 317-22.
160. Kobayashi T, Kuroda J, Ashihara E, et al. Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways. Leukemia 2010; 24: 843-50.
161. Eshkar Sebban L, Ronen D, Levartovsky D, et al. The involvement of CD44 and its novel ligand galectin-8 in apoptotic regulation of autoimmune inflammation. J Immunol 2007; 179: 1225-35.
162. Arbel-Goren R, Levy Y, Ronen D, Zick Y. Cyclin-dependent kinase inhibitors and JNK act as molecular switches, regulating the choice between growth arrest and apoptosis induced by galectin-8. J Biol Chem 2005; 280: 19105-14.
163. Cattaneo V, Tribulatti MV, Campetella O. Galectin-8 tandemrepeat structure is essential for T-cell proliferation but not for co-stimulation. Biochem J 2011; 434: 153-60.
164. Tribulatti MV, Cattaneo V, Hellman U, Mucci J, Campetella O. Galectin-8 provides costimulatory and proliferative signals to T lymphocytes. J Leukoc Biol 2009; 86: 371-80.
165. Tribulatti MV, Mucci J, Cattaneo V, et al. Galectin-8 induces apoptosis in the CD4(high)CD8(high) thymocyte subpopulation. Glycobiology 2007; 17: 1404-12.
166. Norambuena A, Metz C, Vicuna L, et al. Galectin-8 induces apoptosis in Jurkat T cells by phosphatidic acid-mediated ERK1/2 activation supported by protein kinase A downregulation. J Biol Chem 2009; 284: 12670-9.
167. Ideo H, Seko A, Yamashita K. Galectin-4 binds to sulfated glycosphingolipids and carcinoembryonic antigen in patches on the cell surface of human colon adenocarcinoma cells. J Biol Chem 2005; 280: 4730-7.
168. Ideo H, Seko A, Yamashita K. Recognition mechanism of galectin-4 for cholesterol 3-sulfate. J Biol Chem 2007; 282: 21081-9.
169. Strott CA, Higashi Y. Cholesterol sulfate in human physiology: what's it all about? J Lipid Res 2003; 44: 1268-78.
170. Williams ML, Hughes-Fulford M, Elias PM. Inhibition of 3- hydroxy-3-methylglutaryl coenzyme A reductase activity and sterol synthesis by cholesterol sulfate in cultured fibroblasts. Biochim Biophys Acta 1985; 845: 349-57.
171. Huflejt ME, Jordan ET, Gitt MA, Barondes SH, Leffler H. Strikingly different localization of galectin-3 and galectin-4 in human colon adenocarcinoma T84 cells. Galectin-4 is localized at sites of cell adhesion. J Biol Chem 1997; 272: 14294-303.
172. Hokama A, Mizoguchi E, Sugimoto K, et al. Induced reactivity of intestinal CD4(+) T cells with an epithelial cell lectin, galectin-4, contributes to exacerbation of intestinal inflammation. Immunity 2004; 20: 681-93.
173. Paclik D, Danese S, Berndt U, Wiedenmann B, Dignass A, Sturm A. Galectin-4 controls intestinal inflammation by selective regulation of peripheral and mucosal T cell apoptosis and cell cycle. PLoS ONE 2008; 3: e2629.
174. Matarrese P, Tinari N, Semeraro ML, Natoli C, Iacobelli S, Malorni W. Galectin-3 overexpression protects from cell damage and death by influencing mitochondrial homeostasis. FEBS Lett 2000; 473: 311-5.
175. Fukumori T, Takenaka Y, Yoshii T, et al. CD29 and CD7 mediate galectin-3-induced type II T-cell apoptosis. Cancer Res 2003; 63: 8302-11.
176. Stillman BN, Hsu DK, Pang M, et al. Galectin-3 and galectin- 1 bind distinct cell surface glycoprotein receptors to induce T cell death. J Immunol 2006; 176: 778-89.
177. Hughes RC. Galectins as modulators of cell adhesion. Biochimie 2001; 83: 667-76.
178. Dong S, Hughes RC. Galectin-3 stimulates uptake of extracellular Ca2+ in human Jurkat T-cells. FEBS Lett 1996; 395: 165-9.
179. Demetriou M, Granovsky M, Quaggin S, Dennis JW. Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation. Nature 2001; 409: 733-9.
180. Sano H, Hsu DK, Apgar JR, et al. Critical role of galectin-3 in phagocytosis by macrophages. J Clin Invest 2003; 112: 389-97.
181. Howes MT, Kirkham M, Riches J, et al. Clathrin-independent carriers form a high capacity endocytic sorting system at the leading edge of migrating cells. J Cell Biol 2010; 190: 675-91.
182. Schneider D, Greb C, Koch A, et al. Trafficking of galectin-3 through endosomal organelles of polarized and nonpolarized cells. Eur J Cell Biol 2010; 89: 788-98.
183. Liu W, Hsu DK, Chen HY, et al. Galectin-3 Regulates Intracellular Trafficking of EGFR through Alix and Promotes Keratinocyte Migration. J Invest Dermatol 2012; 132: 2828-37.
184. Falguieres T, Luyet PP, Bissig C, Scott CC, Velluz MC, Gruenberg J. In vitro budding of intralumenal vesicles into late endosomes is regulated by Alix and Tsg101. Mol Biol Cell 2008; 19: 4942-55.
185. Probstmeier R, Montag D, Schachner M. Galectin-3, a betagalactoside- binding animal lectin, binds to neural recognition molecules. J Neurochem 1995; 64: 2465-72.
186. Delacour D, Cramm-Behrens CI, Drobecq H, Le Bivic A, Naim HY, Jacob R. Requirement for galectin-3 in apical protein sorting. Curr Biol 2006; 16: 408-14.
187. Delacour D, Koch A, Ackermann W, et al. Loss of galectin-3 impairs membrane polarisation of mouse enterocytes in vivo. J Cell Sci 2008; 121: 458-65.
188. Ohannesian DW, Lotan D, Thomas P, et al. Carcinoembryonic antigen and other glycoconjugates act as ligands for galectin-3 in human colon carcinoma cells. Cancer Res 1995; 55: 2191-9.
189. Mazurek N, Byrd JC, Sun Y, et al. Cell-surface galectin-3 confers resistance to TRAIL by impeding trafficking of death receptors in metastatic colon adenocarcinoma cells. Cell Death Differ 2012; 19: 523-33.
190. Fukumori T, Oka N, Takenaka Y, et al. Galectin-3 regulates mitochondrial stability and antiapoptotic function in response to anticancer drug in prostate cancer. Cancer Res 2006; 66: 3114-9.
191. Clark MC, Pang M, Hsu DK, et al. Galectin-3 binds to CD45 on diffuse large B-cell lymphoma cells to regulate susceptibility to cell death. Blood 2012; 120: 4635-44.
192. Sato S, Hughes RC. Binding specificity of a baby hamster kidney lectin for H type I and II chains, polylactosamine glycans, and appropriately glycosylated forms of laminin and fibronectin. J Biol Chem 1992; 267: 6983-90.
193. Zhou Q, Cummings RD. The S-type lectin from calf heart tissue binds selectively to the carbohydrate chains of laminin. Arch Biochem Biophys 1990; 281: 27-35.
194. Ozeki Y, Matsui T, Yamamoto Y, Funahashi M, Hamako J, Titani K. Tissue fibronectin is an endogenous ligand for galectin-1. Glycobiology 1995; 5: 255-61.
195. Goetz JG, Joshi B, Lajoie P, et al. Concerted regulation of focal adhesion dynamics by galectin-3 and tyrosinephosphorylated caveolin-1. J Cell Biol 2008; 180: 1261-75.
196. Levy Y, Ronen D, Bershadsky AD, Zick Y. Sustained induction of ERK, protein kinase B, and p70 S6 kinase regulates cell spreading and formation of F-actin microspikes upon ligation of integrins by galectin-8, a mammalian lectin. J Biol Chem 2003; 278: 14533-42.
197. Alge-Priglinger CS, Andre S, Kreutzer TC, et al. Inhibition of human retinal pigment epithelial cell attachment, spreading, and migration by the human lectin galectin-1. Mol Vis 2009; 15: 2162-73.
198. Espelt MV, Croci DO, Bacigalupo ML, et al. Novel roles of galectin-1 in hepatocellular carcinoma cell adhesion, polarization, and in vivo tumor growth. Hepatology 2011; 53: 2097-106.
199. Saravanan C, Liu FT, Gipson IK, Panjwani N. Galectin-3 promotes lamellipodia formation in epithelial cells by interacting with complex N-glycans on alpha3beta1 integrin. J Cell Sci 2009; 122: 3684-93.
200. Alge-Priglinger CS, Andre S, Schoeffl H, et al. Negative regulation of RPE cell attachment by carbohydratedependent cell surface binding of galectin-3 and inhibition of the ERK-MAPK pathway. Biochimie 2011; 93: 477-88.
201. Diskin S, Chen WS, Cao Z, et al. Galectin-8 promotes cytoskeletal rearrangement in trabecular meshwork cells through activation of Rho signaling. PLoS One 2012; 7: e44400.
202. Matarrese P, Fusco O, Tinari N, et al. Galectin-3 overexpression protects from apoptosis by improving cell adhesion properties. Int J Cancer 2000; 85: 545-54.
203. van den Brule FA, Liu FT, Castronovo V. Transglutaminasemediated oligomerization of galectin-3 modulates human melanoma cell interactions with laminin. Cell Adhes Commun 1998; 5: 425-35.
204. Mehul B, Bawumia S, Hughes RC. Cross-linking of galectin 3, a galactose-binding protein of mammalian cells, by tissuetype transglutaminase. FEBS Lett 1995; 360: 160-4.
205. Le Marer N, Hughes RC. Effects of the carbohydrate-binding protein galectin-3 on the invasiveness of human breast carcinoma cells. J Cell Physiol 1996; 168: 51-8.
206. Larsen M, Artym VV, Green JA, Yamada KM. The matrix reorganized: extracellular matrix remodeling and integrin signaling. Curr Opin Cell Biol 2006; 18: 463-71.
207. Partridge EA, Le Roy C, Di Guglielmo GM, et al. Regulation of cytokine receptors by Golgi N-glycan processing and endocytosis. Science 2004; 306: 120-4.
208. Reticker-Flynn NE, Malta DF, Winslow MM, et al. A combinatorial extracellular matrix platform identifies cellextracellular matrix interactions that correlate with metastasis. Nat Commun 2012; 3: 1122.
209. Dalotto-Moreno T, Croci DO, Cerliani JP, et al. Targeting galectin-1 overcomes breast cancer associated immunosuppression and prevents metastatic disease. Cancer Res 2013; 73: 1107-17.
210. Klibi J, Niki T, Riedel A, et al. Blood diffusion and Th1- suppressive effects of galectin-9-containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells. Blood 2009; 113: 1957-66.
211. Welton JL, Khanna S, Giles PJ, et al. Proteomics analysis of bladder cancer exosomes. Mol Cell Proteomics 2010; 9: 1324-38.
212. Carlsson MC, Balog CI, Kilsgard O, et al. Different fractions of human serum glycoproteins bind galectin-1 or galectin-8, and their ratio may provide a refined biomarker for pathophysiological conditions in cancer and inflammatory disease. Biochim Biophys Acta 2012; 1820: 1366-72.
213. Cederfur C, Salomonsson E, Nilsson J, et al. Different affinity of galectins for human serum glycoproteins: galectin-3 binds many protease inhibitors and acute phase proteins. Glycobiology 2008; 18: 384-94.
214. Romaniuk MA, Tribulatti MV, Cattaneo V, et al. Human platelets express and are activated by galectin-8. Biochem J 2010; 432: 535-47.
215. Gruson D, Ko G. Galectins testing: new promises for the diagnosis and risk stratification of chronic diseases? Clin Biochem 2012; 45: 719-26.
216. Iwamoto M, Taguchi C, Sasaguri K, et al. The Galectin-1 level in serum as a novel marker for stress. Glycoconj J 2010; 27: 419-25.
217. Hirabayashi J, Hashidate T, Arata Y, et al. Oligosaccharide specificity of galectins: a search by frontal affinity chromatography. Biochim Biophys Acta 2002; 1572: 232-54.
218. Yang RY, Rabinovich GA, Liu FT. Galectins: structure, function and therapeutic potential. Expert Rev Mol Med 2008; 10: e17.
219. Fuster MM, Esko JD. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer 2005; 5: 526-42.
220. Lagana A, Goetz JG, Cheung P, Raz A, Dennis JW, Nabi IR. Galectin binding to Mgat5-modified N-glycans regulates fibronectin matrix remodeling in tumor cells. Mol Cell Biol 2006; 26: 3181-93.
221. Krzeminski M, Singh T, Andre S, et al. Human galectin-3 (Mac-2 antigen): defining molecular switches of affinity to natural glycoproteins, structural and dynamic aspects of glycan binding by flexible ligand docking and putative regulatory sequences in the proximal promoter region. Biochim Biophys Acta 2011; 1810: 150-61.
222. Vokhmyanina OA, Rapoport EM, Andre S, et al. Comparative study of the glycan specificities of cell-bound human tandemrepeat- type galectin-4, -8 and -9. Glycobiology 2012; 22: 1207-17.
223. Wu AM, Singh T, Liu JH, et al. Adhesion/growth-regulatory galectins: insights into their ligand selectivity using natural glycoproteins and glycotopes. Adv Exp Med Biol 2011; 705: 117-41.
224. Al-Ansari S, Zeebregts CJ, Slart RH, Peppelenbosch M, Tio RA. Galectins in atherosclerotic disease. Trends Cardiovasc Med 2009; 19: 164-9.
225. Liu X, Feng Q, Chen Y, et al. Proteomics-based identification of differentially-expressed proteins including galectin-1 in the blood plasma of type 2 diabetic patients. J Proteome Res 2009; 8: 1255-62.
226. Weigert J, Neumeier M, Wanninger J, et al. Serum galectin-3 is elevated in obesity and negatively correlates with glycosylated hemoglobin in type 2 diabetes. J Clin Endocrinol Metab 2010; 95: 1404-11.
227. de Boer RA, Yu L, van Veldhuisen DJ. Galectin-3 in cardiac remodeling and heart failure. Curr Heart Fail Rep 2010; 7: 1-8.
228. Sharma UC, Pokharel S, van Brakel TJ, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004; 110: 3121-8.
229. van Kimmenade RR, Januzzi JL, Jr., Ellinor PT, et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 2006; 48: 1217-24.
230. Freitag N, Tirado-Gonzalez I, Barrientos G, et al. Interfering with Gal-1-mediated angiogenesis contributes to the pathogenesis of preeclampsia. Proc Natl Acad Sci U S A 2013; 110: 11451-6.
231. Ramhorst RE, Giribaldi L, Fraccaroli L, et al. Galectin-1 confers immune privilege to human trophoblast: implications in recurrent fetal loss. Glycobiology 2012; 22: 1374-86.
232. Blois SM, Ilarregui JM, Tometten M, et al. A pivotal role for galectin-1 in fetomaternal tolerance. Nat Med 2007; 13: 1450-7.
233. Odegard RA, Vatten LJ, Nilsen ST, Salvesen KA, Austgulen R. Preeclampsia and fetal growth. Obstet Gynecol 2000; 96: 950-5.
234. Sammar M, Nisemblat S, Fleischfarb Z, et al. Placentabound and body fluid PP13 and its mRNA in normal pregnancy compared to preeclampsia, HELLP and preterm delivery. Placenta 2011; 32 Suppl: S30-6.
235. Hittelet A, Legendre H, Nagy N, et al. Upregulation of galectins-1 and -3 in human colon cancer and their role in regulating cell migration. Int J Cancer 2003; 103: 370-9.
236. Schoeppner HL, Raz A, Ho SB, Bresalier RS. Expression of an endogenous galactose-binding lectin correlates with neoplastic progression in the colon. Cancer 1995; 75: 2818-26.
237. Zaia Povegliano L, Oshima CT, de Oliveira Lima F, Andrade Scherholz PL, Manoukian Forones N. Immunoexpression of galectin-3 in colorectal cancer and its relationship with survival. J Gastrointest Cancer 2011; 42: 217-21.
238. Watanabe M, Takemasa I, Kaneko N, et al. Clinical significance of circulating galectins as colorectal cancer markers. Oncol Rep 2011; 25: 1217-26.
239. Wiseman SM, Melck A, Masoudi H, et al. Molecular phenotyping of thyroid tumors identifies a marker panel for differentiated thyroid cancer diagnosis. Ann Surg Oncol 2008; 15: 2811-26.
240. Chiu CG, Strugnell SS, Griffith OL, et al. Diagnostic utility of galectin-3 in thyroid cancer. Am J Pathol 2010; 176: 2067-81.
241. Compagno D, Laderach DJ, Gentilini L, Jaworski FM, Rabinovich GA. Delineating the galectin signature of the tumor microenvironment. Oncoimmunology 2013; 2: e23565.
242. van den Brule FA, Waltregny D, Liu FT, Castronovo V. Alteration of the cytoplasmic/nuclear expression pattern of galectin-3 correlates with prostate carcinoma progression. Int J Cancer 2000; 89: 361-7.
243. Carlsson MC, Cederfur C, Schaar V, et al. Galectin-1-binding glycoforms of haptoglobin with altered intracellular trafficking, and increase in metastatic breast cancer patients. PLoS One 2011; 6: e26560.
244. Giordano M, Croci DO, Rabinovich GA. Galectins in hematological malignancies. Curr Opin Hematol 2013; 20: 327-35.
245. Boscher C, Dennis JW, Nabi IR. Glycosylation, galectins and cellular signaling. Curr Opin Cell Biol 2011; 23: 383-92.